Ablation of type-1 IFN signaling in hematopoietic cells confers protection following traumatic brain injury

Karve, IP; Zhang, M; Habgood, M; Frugier, T; Brody, KM; Sashindranath, M; Ek, CJ; Chappaz, S; Kile, BT; Wright, D; Wang, H; Johnston, L; Daglas, M; Ates, RC; Medcalf, RL; Taylor, JM; Crack, PJ

Author(s): Karve, IP; Zhang, M; Habgood, M; Frugier, T; Brody, KM; Sashindranath, M; Ek, CJ; Chappaz, S; Kile, BT; Wright, D; Wang, H; Johnston, L; Daglas, M; Ates, RC; Medcalf, RL; Taylor, JM; Crack, PJ;
Details: Publication Year 2016,Volume 3,Issue #1,Page pii: ENEURO.0128-15.2016
Journal Title: eNeuro
Publication Type: Journal Article
Abstract: Type-1 interferons (IFNs) are pleiotropic cytokines that signal through the type-1 IFN receptor (IFNAR1). Recent literature has implicated the type-1 IFNs in disorders of the CNS. In this study, we have investigated the role of type-1 IFNs in neuroinflammation following traumatic brain injury (TBI). Using a controlled cortical impact model, TBI was induced in 8- to 10-week-old male C57BL/6J WT and IFNAR1(-/-) mice and brains were excised to study infarct volume, inflammatory mediator release via quantitative PCR analysis and immune cell profile via immunohistochemistry. IFNAR1(-/-) mice displayed smaller infarcts compared with WT mice after TBI. IFNAR1(-/-) mice exhibited an altered anti-inflammatory environment compared with WT mice, with significantly reduced levels of the proinflammatory mediators TNFalpha, IL-1beta and IL-6, an up-regulation of the anti-inflammatory mediator IL-10 and an increased activation of resident and peripheral immune cells after TBI. WT mice injected intravenously with an anti-IFNAR1 blocking monoclonal antibody (MAR1) 1 h before, 30 min after or 30 min and 2 d after TBI displayed significantly improved histological and behavioral outcome. Bone marrow chimeras demonstrated that the hematopoietic cells are a peripheral source of type-1 IFNs that drives neuroinflammation and a worsened TBI outcome. Type-1 IFN mRNA levels were confirmed to be significantly altered in human postmortem TBI brains. Together, these data demonstrate that type-1 IFN signaling is a critical pathway in the progression of neuroinflammation and presents a viable therapeutic target for the treatment of TBI.
Publisher: Society for Neuroscience
Research Division(s): Chemical Biology
PubMed ID: 27022620
Link To PubMed Central Version: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757777/
Publisher's Version: https://doi.org/10.1523/ENEURO.0128-15.2016
Open Access at Publisher's Site: http://dx.doi.org/10.1523/ENEURO.0128-15.2016
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2016-04-05 01:43:58

Last Modified: 2016-04-05 02:11:13